Chronic Pain News and Research

RSS

Medasys Prometra programmable implantable drug pump receives FDA PMA approval

Medasys Inc., a medical device company focused on providing implantable drug delivery solutions, announced today that it has received PMA approval from the U. S. Food and Drug Administration for its Prometra programmable implantable drug pump.

13 Feb 2012

Single fibronectin injection can prevent chronic pain development after SCI

Chronic neuropathic pain following a spinal cord injury is common and very difficult to treat, but a new therapeutic strategy requiring a one-time injection into the spinal column has potential to improve patient outcomes.

9 Feb 2012

Valley Pain Consultants announces new office location

Valley Pain Consultants, a division of Valley Anesthesiology Consultants, announced the relocation of its Paradise Valley office to 3301 N. Miller Road, Suite 120, Scloottsdale, AZ 85251.

9 Feb 2012

Comprehensive program to help reduce health risks of narcotics drugs on injured workers

Accident Fund Holdings, Inc. recently created a comprehensive narcotics program to help reduce the health risks of these drugs on injured workers and ultimately provide a mechanism for them to get back to work sooner.

6 Feb 2012

Takeda, SPI announce that lubiprostone phase 3 trial on OBD meets primary endpoint

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.

2 Feb 2012

BU scientists create unique material and drug delivery mechanism

Long duration, controllable drug delivery is of wide interest to medical researchers and clinicians, particularly those seeking to improve treatment for patients with chronic pain or to prevent cancer recurrence after surgery. Now a team of researchers led by Boston University Biomedical Engineer and Chemist Mark Grinstaff has developed a unique material and drug delivery mechanism that could pave the way for implants that release a drug at a designated rate for months.

1 Feb 2012

Women feel pain more than men: Study

A new study showed that women experience more intense pain than men. The study published in the Jan. 23 issue of the Journal of Pain, further suggests that greater effort is needed to recruit women into studies in order to determine the reasons for this gender difference. The Stanford University School of Medicine investigators examined pain scores from tens of thousands of patients in the United States.

24 Jan 2012

Scientists use metabolomics to discover DMS linked with neuropathic pain

Millions of people worldwide suffer from a type of chronic pain called neuropathic pain, which is triggered by nerve damage. Precisely how this pain persists has been a mystery, and current treatments are largely ineffective. But a team led by scientists from The Scripps Research Institute, using a new approach known as metabolomics, has now discovered a major clue: dimethylsphingosine (DMS), a small-molecule byproduct of cellular membranes in the nervous system.

23 Jan 2012

Viewpoints: Health care and the federal deficit; Doctors reassessing health law

We don't have a generalized overspending problem. We have a humongous health-care problem. … Try to ignore the current shallowness in American politics, if you can, and assume that the federal budget deficit will be among the major issues of the 2012 campaign. It certainly should be, for while everyone wants a lower deficit, the two parties have starkly different visions of how to get there.

20 Jan 2012

Geisinger, InVivo to conduct injectable biocompatible hydrogel preclinical study for PNI

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), and Geisinger Health System today announced a research collaboration to conduct a preclinical study using InVivo's injectable biocompatible hydrogel for the treatment of chronic pain caused by peripheral nerve compression.

17 Jan 2012

Researchers discover previously unknown effect of opioids

A team of researchers at the MedUni Vienna's Department of Neurophysiology has discovered a previously unknown effect of opioids: the study, which has now been published in the highly respected magazine "Science" and was led by Ruth Drdla-Schutting and Jürgen Sandkühler, shows that opioids not only temporarily relieve pain, but at the right dose can also erase memory traces of pain in the spinal cord and therefore eliminate a key cause of chronic pain.

13 Jan 2012

HealthSaaS enters innovative alliance with iMPak for chronic pain management and medication adherence

The iMPak Health Journal for Pain empowers patients to easily record their pain levels before and after their prescribed medication regimen, providing physicians with readily available, useful, patient information.

11 Jan 2012

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne.

9 Jan 2012

Endo enters global development agreement with BDSI for BEMA Buprenorphine

Endo Pharmaceuticals announced today it has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International for BEMA Buprenorphine.

6 Jan 2012

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

BioDelivery Sciences International, Inc. today announced the signing of a worldwide license and development agreement with Endo Pharmaceuticals for the exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain.

6 Jan 2012

Arcion receives U.S. patent allowance for ARC-2022 to treat PHN

Arcion Therapeutics, a clinical stage biotechnology company developing topical therapies for chronic pain, today announced that it received notice of allowance for a US Patent for its high strength gel formulation of topical lidocaine, ARC-2022.

5 Jan 2012

Ampio completes enrollment phase of Australian Ampion In Knee trials

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that it is has completed the expanded patient enrollment phase of its Ampion In Knee (AIK) trials in Australia.

3 Jan 2012